Insmed (INSM) Revenue Growth (3y) (2013 - 2026)
Powered by 
Analysis
Insmed (INSM) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 12.90% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 5.75% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 10.17% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 10.76% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 77.85% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -25.02% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 59.40% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 3.66% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 76.62% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -12.40% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 76.62% |
| Mar 31, 2026 | 67.41% |
| Dec 31, 2025 | 64.47% |
| Sep 30, 2025 | 28.09% |
| Jun 30, 2025 | 18.09% |
| Mar 31, 2025 | 20.46% |
| Dec 31, 2024 | 23.00% |
| Sep 30, 2024 | 25.95% |
| Jun 30, 2024 | 25.81% |
| Mar 31, 2024 | 23.36% |
| Dec 31, 2023 | 26.43% |
| Sep 30, 2023 | 21.91% |
| Jun 30, 2023 | 22.03% |
| Mar 31, 2023 | 20.95% |
| Dec 31, 2022 | 9.07% |
| Sep 30, 2022 | 20.32% |
| Jun 30, 2022 | 29.59% |
| Mar 31, 2022 | 34.35% |
| Dec 31, 2021 | 78.70% |
| Jun 30, 2013 | 83.41% |